AA
TAK icon

Addison Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Addison Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,170
Closed -$40.2K – 975
2026
Q1 		$40.2K Hold
2,170
– – 0.01% 460
2025
Q4 		$33.8K Sell
2,170
-351
-14% -$5.02K 0.01% 477
2025
Q3 		$36.9K Buy
2,521
+351
+16% +$5.21K 0.01% 452
2025
Q2 		$33.5K Buy
2,170
+97
+5% +$1.43K 0.01% 459
2025
Q1 		$30.8K Sell
2,073
-38
-2% -$532 0.01% 437
2024
Q4 		$27.9K Sell
2,111
-12,497
-86% -$172K 0.01% 460
2024
Q3 		$208K Buy
14,608
+13,091
+863% +$186K 0.06% 206
2024
Q2 		$19.6K Buy
+1,517
New +$20.1K 0.01% 490
2024
Q1 		– Sell
-496
Closed -$7.08K – 739
2023
Q4 		$7.08K Buy
+496
New +$7.04K ﹤0.01% 551
2022
Q3 		– Sell
-3,580
Closed -$50K – 767
2022
Q2 		$50K Buy
3,580
+250
+8% +$3.57K 0.03% 263
2022
Q1 		$48K Buy
+3,330
New +$48.9K 0.03% 295

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Addison Advisors's TAK Position: Q2 2026 in Review

Addison Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 2,170 shares — an estimated $40.2K sold.

Addison Advisors first reported a position in TAK in Q1 2022 and held it in 11 quarters. The position peaked at $208K in Q3 2024. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Addison Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Addison Advisors sold 2,170 Takeda Pharmaceutical shares in Q2 2026, an estimated $40.2K.
  • Addison Advisors first reported a position in Takeda Pharmaceutical in Q1 2022 and held it in 11 quarters.
  • Addison Advisors's Takeda Pharmaceutical position peaked at $208K in Q3 2024.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.